# Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

> **NCT00850044** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 87 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** ABT-450
- **DRUG:** ritonavir
- **DRUG:** placebo for ABT-450
- **DRUG:** Placebo for ritonavir

## Key facts

- **NCT ID:** NCT00850044
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-07
- **Final completion:** —
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00850044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00850044, "Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00850044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*